Drug Type Trispecific T-cell engager (TriTE) |
Synonyms SAR 442257 |
Target |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD3 modulators(T cell surface glycoprotein CD3 modulators), CD38 modulators(Lymphocyte differentiation antigen CD38 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin's lymphoma refractory | Phase 1 | US | 24 Jul 2020 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | CZ | 24 Jul 2020 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | NO | 24 Jul 2020 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | KR | 24 Jul 2020 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | ES | 24 Jul 2020 | |
Relapse multiple myeloma | Phase 1 | US | 24 Jul 2020 | |
Relapse multiple myeloma | Phase 1 | CZ | 24 Jul 2020 | |
Relapse multiple myeloma | Phase 1 | NO | 24 Jul 2020 | |
Relapse multiple myeloma | Phase 1 | KR | 24 Jul 2020 | |
Relapse multiple myeloma | Phase 1 | ES | 24 Jul 2020 |
Not Applicable | - | bhqinpxbtn(jboakplhka) = zelnwehvek unoevidnzw (oprktehjgr ) | - | 11 Dec 2023 |